IONS
Ionis Pharmaceuticals, Inc.
Stock
$43.54−0.46 (−1.05%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $1.5B | $2.0B | $1.6B | $1.7B | $1.5B | $1.5B | $1.9B | $2.5B | $2.1B | $1.0B | $665M | $779M | $729M | $657M | $374M | $344M | $472M | $574M | $224M |
| Inventory | $51M | $10M | $13M | $7.4M | $22M | $25M | $22M | $18M | $8.6M | $10.0M | — | — | — | — | — | — | — | — | — |
| Current assets | $2.5B | $3.0B | $2.6B | $2.6B | $2.2B | $2.3B | $2.1B | $2.7B | $2.2B | $1.2B | $798M | $837M | $837M | $736M | $423M | $360M | $483M | $596M | — |
| Intangible assets | — | — | — | — | — | $29M | $28M | $26M | $24M | $22M | $20M | — | — | — | — | — | — | — | — |
| Total assets | $3.0B | $3.5B | $3.0B | $3.0B | $2.5B | $2.6B | $2.4B | $3.2B | $2.7B | $1.3B | $912M | $948M | $956M | $847M | $546M | $485M | $550M | $657M | — |
| Current liabilities | $316M | $782M | $309M | $448M | $312M | $241M | $599M | $273M | $280M | $244M | $134M | $149M | $115M | $98M | $74M | $76M | $106M | $111M | — |
| Long-term debt | — | $1.3B | $1.2B | $1.2B | $1.2B | — | $539M | $786M | — | — | — | — | — | — | — | $146M | $149M | $11M | — |
| Total liabilities | $2.6B | $3.0B | $2.4B | $2.6B | $2.0B | $1.8B | $1.6B | $1.5B | $1.5B | $957M | $813M | $747M | $698M | $469M | $363M | $313M | $306M | $355M | — |
| Shareholders' equity | $440M | $489M | $588M | $387M | $573M | $772M | $743M | $1.5B | $1.0B | $281M | $100M | $201M | $258M | $378M | $183M | $171M | $245M | $292M | $147M |
| Shares outstanding | 166.2M | 165.2M | 159.0M | 145.8M | 143.0M | 141.7M | 176.1M | 174.0M | 173.0M | 78.4M | 77.3M | 75.4M | 74.4M | 73.3M | 63.6M | 62.6M | 62.2M | — | — |
| Current ratio | 7.89 | 3.83 | 8.47 | 5.90 | 7.07 | 9.75 | 3.56 | 9.97 | 7.88 | 4.80 | 5.96 | 5.62 | 7.25 | 7.52 | 5.70 | 4.73 | 4.56 | 5.35 | — |